Next Article in Journal
Evolution of Radiation Fields from Involved Field to Involved Site—A Summary of the Current Guidelines by the International Lymphoma Radiation Oncology Group
Previous Article in Journal
Understanding the Role of Bispecific Antibodies in the Management of B-Cell Non-Hodgkin Lymphoma: A New Immunotherapy That Is Here to Stay
 
 
Commentary
Peer-Review Record

It Is Time to Curb the Dogma in Lymphedema Management

Lymphatics 2023, 1(3), 257-261; https://doi.org/10.3390/lymphatics1030016
by Heather Barnhart 1,2
Reviewer 1:
Reviewer 2: Anonymous
Lymphatics 2023, 1(3), 257-261; https://doi.org/10.3390/lymphatics1030016
Submission received: 31 August 2023 / Revised: 29 September 2023 / Accepted: 6 October 2023 / Published: 12 October 2023

Round 1

Reviewer 1 Report

This is a very well-written commentary on an important topic. It could be improved and of greater benefit if the author would end the commentary with a few clear examples of specific proposed changes that would be meaningful and important to the management of the lymphedematous patient.

Author Response

Thank you for your kind review and suggestions.  I have added additional supporting evidence and examples per your request.  The new information is highlighted and can be found at lines 80-110, along with new references.

 

Reviewer 2 Report

It was a pleasure to review the manuscript It’s Time to Curb the Dogma in Lymphedema Management.  Barnhart and colleagues present a commentary highlighting importance of embracing lymphedema, with a call to action to challenge historic non-evidence driven management.  The focus of this manuscript is three-fold; 1- To highlight the importance of a significant disease process affecting patient quality of life and the health care system, 2- To excite new exploration in lymphedema evaluation and management, and 3- To highlight cultural resistance to change.    

 

Comments for the authors:

Consider including and highlighting literature that challenge historic dogma. 

  1. Literature that demonstrates a recent shift in secondary lymphedema (especially breast cancer related lymphedema) from traditional impairment models to prospective screening models.  Such as the recent PREVENT Trial.  Along with recent literature on the development of prospective screening programs.
  2. Literature supporting institution of novel surgical techniques for prevention such as immediate lymphatic reconstruction surgeries for lymphedema prevention (LYMPHA – lymphatic microsurgical healing approach)

Overall, I enjoyed reading this commentary and believe that it adds a new light to the literature regarding a significant health care problem.  I believe this manuscript demonstrates passion to advance understanding into lymphedema and challenge established non-evidence-based norms.

Author Response

Thank you kindly for your supportive review.  I have added content per your suggestions which is highlighted in lines 80-110, along with new references.

Most appreciated!

Back to TopTop